- Home
- / NATCO Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
NATCO Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₹1.5 K
2024-08-30
Market Capitalization
₹275.4 B
2024-08-30
Revenue
₹40 B
FY, 2024
CreditSafe Score
?
Score changed on Sept 20, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 21.5B | 20.5B | 18.9B | 16.9B | 19.0B | 27.0B | 40.0B |
| Cost of goods sold | 4.5B | 3.9B | 4.1B | 5.4B | 6.0B | 6.6B | 7.2B |
| Gross profit | 17.4B | 17.0B | 15.1B | 15.2B | 13.5B | 20.6B | 34.1B |
| Gross profit margin, % | 80.7% | 83.1% | 79.8% | 90.0% | 71.0% | 76.3% | 85.3% |
| Operating expense total | 8.1B | 9.1B | 9.2B | 9.1B | 10.6B | 11.3B | 15.3B |
| Depreciation and amortization | 662.0M | 810.0M | 998.0M | 1.2B | 1.4B | 1.6B | 1.9B |
| EBITDA | 9.3B | 7.9B | 5.9B | 6.1B | 3.0B | 9.3B | 18.8B |
| EBITDA margin, % | 43.2% | 38.8% | 31.1% | 36.4% | 15.5% | 34.3% | 47.0% |
| EBIT | 8.6B | 7.2B | 4.9B | 5.0B | 1.5B | 7.6B | 16.9B |
| EBIT margin, % | 40.2% | 34.9% | 25.9% | 29.4% | 8.1% | 28.3% | 42.3% |
| Interest income | 249.0M | 898.0M | 791.0M | 566.0M | 390.0M | 512.0M | |
| Interest expense | 154.0M | 193.0M | 215.0M | 133.0M | 177.0M | 145.0M | 192.0M |
| Pre tax profit | 8.9B | 8.2B | 5.7B | 5.8B | 2.0B | 8.6B | 16.7B |
| Income tax expense | 1.9B | 1.8B | 1.1B | 1.4B | 322.0M | 1.5B | 2.9B |
| Net Income | 7.0B | 6.4B | 4.6B | 4.4B | 1.7B | 7.2B | 13.9B |